Chloroquine nasal drops in asymptomatic & mild COVID-19: An exploratory randomized clinical trial

https://doi.org/10.4103/ijmr.IJMR_3665_20

Nasal CQN was associated with local irritation in seven and non-compliance in one of 30 patients. Clinical recovery was noted as similar with 100 per cent asymptomatic by day seven in both arms. Virological outcomes also indicated similarly improving Ct values in both arms, and similar proportion of patients transitioning to non-infectivity by day 10 (controls – 19/25; nasal CQN – 15/24).  Patients receiving nasal CQN (n=5) demonstrated stable Ct values from day 0 to 10, while patients with no nasal CQN (n=4) demonstrated significant dip in Ct value indicating to infection (Ct<35) and infectivity (Ct<33). Interpretation & conclusions: The present study suggests to the potential of topical nasal CQN in the prevention of COVID-19 infection if administered before the infection is established. No significant differences in clinical or virological outcome were however, demonstrated in patients with mild but established illness.

Tags: